Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

254 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.
Sartor O, Goeckeler W, Bruland O. Sartor O, et al. Asian J Androl. 2011 Nov;13(6):783-4. doi: 10.1038/aja.2011.120. Epub 2011 Aug 22. Asian J Androl. 2011. PMID: 21857688 Free PMC article. No abstract available.
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Lipton A, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s. doi: 10.1158/1078-0432.CCR-06-1213. Clin Cancer Res. 2006. PMID: 17062702 Free PMC article.
Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge.
Sartor O, Bruland O. Sartor O, et al. Clin Genitourin Cancer. 2011 Sep;9(1):1-2. doi: 10.1016/j.clgc.2011.08.001. Clin Genitourin Cancer. 2011. PMID: 21925102 No abstract available.
Targeted radio-nuclide therapy of skeletal metastases.
Sartor O, Hoskin P, Bruland OS. Sartor O, et al. Cancer Treat Rev. 2013 Feb;39(1):18-26. doi: 10.1016/j.ctrv.2012.03.006. Epub 2012 Apr 24. Cancer Treat Rev. 2013. PMID: 22534284 Review.
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Sartor O, et al. Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24836273 Clinical Trial.
Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
Humm JL, Sartor O, Parker C, Bruland OS, Macklis R. Humm JL, et al. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):898-906. doi: 10.1016/j.ijrobp.2014.12.061. Int J Radiat Oncol Biol Phys. 2015. PMID: 25832684 Review.
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D. Parker C, et al. Eur Urol. 2016 Nov;70(5):875-883. doi: 10.1016/j.eururo.2016.06.002. Epub 2016 Jun 22. Eur Urol. 2016. PMID: 27344296 Clinical Trial.
Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.
Larsen RH, Hoff P, Vergote IB, Bruland OS, Aas M, De Vos L, Nustad K. Larsen RH, et al. Gynecol Oncol. 1995 Apr;57(1):9-15. doi: 10.1006/gyno.1995.1093. Gynecol Oncol. 1995. PMID: 7705707
254 results
Jump to page
Feedback